PatternsRadar
Sign in

ALBERTDAVDAlbert David Limited

NSE
Full chart
839.10INR+2.65 (+0.32%)Close · 6 Oct 2026
6 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹479 CrMarket cap
21.2P/E (TTM)
61.6%Delivery

Filings & corporate actions

41 results filed
CSV
Next results · Q2 FY27
Expected 9 Nov 2026 – 14 Nov 2026
Estimate: filed 40–45 days after quarter end, last 5 times
Dividend
₹5.00 per share · last 30 Jul 2026
2026
  • 6 AugresultsResults · Q1 FY27 · standalone+5.4%NSE
  • 30 JuldividendDividend · ₹5.00 per share+0.2%
  • 18 JulshareholdingShareholding · 30 Jun 2026-0.3%NSE
  • 13 MayresultsResults · Q4 FY26 · standalone-8.2%NSE
  • 20 AprshareholdingShareholding · 31 Mar 2026-0.3%NSE
  • 11 FebresultsResults · Q3 FY26 · standalone+3.7%NSE
  • 17 JanshareholdingShareholding · 31 Dec 2025-2.3%NSE

Reaction to results · all yearsrose on day 0 in 12 of 41 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY276 Aug 2026+5.4%+15.8%+25.6%8.9×
Q4 FY2613 May 2026-8.2%-9.3%-11.0%3.8×
Q3 FY2611 Feb 2026+3.7%+1.0%-5.6%13.2×
Q2 FY2613 Nov 2025-6.3%-9.0%-12.7%3.4×
Q1 FY262 Aug 2025-4.4%-7.9%-8.8%4.7×
Q4 FY2516 May 2025-0.2%-1.9%+4.4%0.8×
Q3 FY2512 Feb 2025-18.2%-18.2%-28.0%16.5×
Q2 FY2514 Nov 2024-3.0%-3.8%+4.5%1.0×
Q1 FY259 Aug 2024-5.2%-3.7%+21.2%1.9×
Q4 FY2414 May 2024-2.9%-3.3%-1.0%2.8×
Q3 FY245 Feb 2024+1.9%-7.7%-8.3%0.9×
Q2 FY249 Nov 2023-0.6%+7.9%+17.9%3.1×
Q1 FY2411 Aug 2023-0.3%-4.0%-3.5%2.5×
Q4 FY2319 May 2023-3.8%-4.6%+1.9%2.6×
Q3 FY2313 Feb 2023-1.3%-2.0%-8.2%1.1×
Q2 FY2312 Nov 2022+4.7%+2.9%+4.3%8.3×
Q1 FY2310 Aug 2022-3.2%-3.2%-1.2%3.5×
Q4 FY2212 May 2022-9.0%-6.6%-6.3%1.3×
Q3 FY2214 Feb 2022-3.0%-15.5%-12.8%0.8×
Q2 FY2213 Nov 2021+0.7%-7.2%-5.4%2.2×
Q1 FY2212 Aug 2021+1.0%-14.1%-7.2%3.0×
Q4 FY2118 Jun 2021-1.2%-0.2%+9.8%0.3×
Q3 FY219 Feb 2021-4.5%-8.6%-9.2%2.9×
Q2 FY2110 Nov 2020+2.9%+2.6%+12.6%3.3×
Q1 FY2124 Aug 2020-8.6%-17.2%-16.6%1.7×
Q4 FY2029 Jun 2020-11.8%-14.5%-18.4%4.9×
Q3 FY2013 Feb 2020-5.1%-12.1%-36.0%1.2×
Q2 FY2014 Nov 2019+2.9%-2.8%-6.2%20.5×
Q1 FY209 Aug 2019+2.1%-4.3%+1.3%6.9×
Q4 FY1929 May 2019-7.0%-12.9%-19.1%3.0×
Q3 FY1926 Feb 2019-1.5%+9.2%+1.8%0.5×
Q2 FY1922 Nov 2018-2.3%+1.2%+4.9%1.3×
Q1 FY1924 Aug 2018+1.0%+29.8%+10.6%0.3×
Q4 FY1827 Jun 2018-3.4%+4.9%-6.5%0.9×
Q3 FY1816 Mar 2018-1.3%-2.7%+0.6%0.4×
Q2 FY1813 Dec 2017-0.9%-1.4%+32.4%1.2×
Q1 FY1821 Sept 2017-0.3%-5.4%-0.3%0.5×
Q4 FY175 Jun 2017-1.4%-3.2%-5.0%0.9×
Q3 FY1717 Feb 2017+0.3%-0.9%-7.9%0.2×
Q2 FY1718 Nov 2016-0.4%+2.9%+7.3%0.3×
Q1 FY177 Sept 2016+1.7%+1.1%+5.0%0.3×
Average-2.2%-3.1%-1.9%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+43.6%
Profit YoY+303.1%
Interest cost YoY+197.5%
Revenue QoQ+18.0%
Profit QoQ—
CAGR2Y3Y4Y5Y6Y7Y
Revenue+0.6%+2.3%+2.9%+5.8%+4.3%+2.1%
Profit-43.5%-27.0%-4.0%-7.7%+17.0%-3.1%

Key data

CSV
Open835.65
Day range823.30 – 847.95
52-week range579.90 – 931.85
From 52w high-10.0%
RSI (14)47.2
ATR (14)29.11
Volume2.8K
Avg volume (20D)4.5K
Rel volume0.62×
Volatility (1Y)32.9%
Turnover₹23.7L
SMA 50 / 200822.57 / 737.58

Delivery percentage

Latest · 6 Oct 202661.6%
20-day avg69.1%
1-year avg69.1%
Percentile (own history)48th
Range9.8–100.0%
Sessions1,731

Over the last 20 sessions ALBERTDAVD settled 69.1% of its traded quantity, which is unusually high for an NSE equity. That is in line with its own one-year average of 69.1%. The latest session ranks higher than 48% of the 1,731 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+0.32%-0.93%-3.57%+19.01%+28.19%+8.08%

Valuation

CSV
Market cap₹479 Cr
P/E (TTM)21.2
EPS (TTM)39.54
Shares outstanding57.07L
Listed14 Jun 2016

Ownership

CSV
Promoter62.24%
Promoter Δ QoQ0.00 pp
Public37.76%
FII0.57%
DII1.64%
Pledged0.00%

Quarterly results · standalone

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)87.289.985.9101.3
YoY chg-11.4%+8.2%+14.6%+43.6%
Net profit (₹ Cr)(3.3)15.3(21.4)32.0
YoY chg-118.3%——+303.1%
Net margin-3.8%17.0%-25.0%31.6%
EPS-5.7926.81-37.5656.07

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 62.24% · public 37.76%
30 Sept 2021: promoter 61.35%31 Dec 2021: promoter 61.64%31 Mar 2022: promoter 61.96%30 Jun 2022: promoter 61.99%30 Sept 2022: promoter 61.99%31 Dec 2022: promoter 61.99%31 Mar 2023: promoter 62.04%30 Jun 2023: promoter 62.04%30 Sept 2023: promoter 62.04%31 Dec 2023: promoter 62.04%31 Mar 2024: promoter 62.13%30 Jun 2024: promoter 62.13%30 Sept 2024: promoter 62.13%31 Dec 2024: promoter 62.13%31 Mar 2025: promoter 62.24%30 Jun 2025: promoter 62.24%30 Sept 2025: promoter 62.24%31 Dec 2025: promoter 62.24%31 Mar 2026: promoter 62.24%30 Jun 2026: promoter 62.24%
2021-092026-06
  • Promoter
  • Public and others
Promoter
62.24%
Public
37.76%
Promoter change
0.00 pp
Filed
18 Jul 2026
FII
0.57%
DII
1.64%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
Standalone
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations93.288.389.189.498.483.174.970.687.289.985.9101.3
Other income12.116.910.423.120.6(9.0)(5.1)22.0(2.1)12.4(24.8)28.0
Total income105.3105.299.5112.4119.174.169.892.685.1102.361.0129.3
Total expenses78.781.781.490.493.984.281.684.287.782.486.393.5
└ Finance costs0.10.10.10.10.10.10.10.60.80.90.40.5
└ Depreciation1.51.71.81.81.71.71.82.42.22.42.72.3
Profit before tax26.523.418.122.125.1(10.2)(11.8)8.4(2.6)19.9(25.2)35.8
Tax expense6.24.75.23.27.1(0.8)(1.5)0.50.74.6(3.8)3.8
Net profit20.318.712.918.818.1(9.4)(10.3)7.9(3.3)15.3(21.4)32.0
EPS35.5732.8022.6333.0231.67-16.45-18.1013.91-5.7926.81-37.5656.07
Net margin21.78%21.20%14.50%21.09%18.36%-11.30%-13.79%11.25%-3.78%17.02%-24.96%31.58%
PBT margin28.49%26.55%20.34%24.69%25.53%-12.23%-15.77%11.96%-2.96%22.13%-29.39%35.32%
Tax rate23.54%20.13%28.72%14.59%28.10%——5.93%—23.11%—10.61%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 6 Aug 2026.

ALBERTDAVD at a glance

  • ALBERTDAVD closed at ₹839.1 on 6 Oct 2026, +0.32% on the day, +8.1% over one year, 10.0% below its 52-week high of ₹931.85.
  • Delivery was 61.6% of traded quantity on 6 Oct 2026, the 48th percentile of its own 1,731 sessions with a reading (20-session average 69.1%, 1-year average 69.1%).
  • Market capitalisation is ₹479 crore at a trailing P/E of 21.2 (trailing EPS ₹39.54).
  • Q1 FY27 results (standalone, filed 6 Aug 2026): revenue ₹101 crore (+43.6% year on year), net profit ₹32 crore (+303.1%); the price moved +5.4% on the first session after.
  • Promoters held 62.24% at 30 Jun 2026, unchanged on the previous filing.
  • Q2 FY27 results are expected between 9 Nov 2026 and 14 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE155C01010
SeriesEQ
Listed14 Jun 2016
History from14 Jun 2016
Sessions2,552

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE